Erasca to Present at Upcoming Investor Conferences in June
Erasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings.
聖地亞哥，2024年5月29日（GLOBE NEWSWIRE）——Erasca, Inc.（納斯達克股票代碼：ERAS）是一家臨床階段的精準腫瘤學公司，專注於爲RAS/MAPK路徑驅動的癌症患者發現、開發和商業化療法。該公司今天宣佈，董事長、首席執行官兼聯合創始人喬納森·林和首席財務官大衛·查科醫學博士兼首席商務官，將參加2024年6月的以下投資者會議，還將參加一對一的投資者會議。
Jefferies Global Healthcare Conference (June 5 – 6, 2024)
Location: Marriott Marquis, New York, NY
Format: Presentation
Date and Time: Thursday, June 6, 10:30 – 10:55 am Eastern Time
傑富瑞全球醫療保健會議（2024 年 6 月 5 日至 6 日）
地點：紐約州紐約馬奎斯萬豪酒店
格式：演示文稿
日期和時間：美國東部時間 6 月 6 日星期四上午 10:30 — 10:55
Goldman Sachs 45th Annual Global Healthcare Conference (June 10 – 13, 2024)
Location: Loews Miami Beach Hotel, Miami Beach, Florida
Format: Fireside Chat
Date and Time: Wednesday, June 12, 10:40 – 11:15 am Eastern Time
高盛 45第四 年度全球醫療保健會議（2024 年 6 月 10 日至 13 日）
地點：佛羅里達州邁阿密海灘洛伊斯邁阿密海灘酒店
格式：爐邊聊天
日期和時間：美國東部時間 6 月 12 日星期三上午 10:40 — 11:15
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
這些活動的網絡直播將在網上播出 erasca.com/Event。網絡直播結束後，將在30天內提供活動的存檔重播 erasca.com/Event。
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team's capabilities and experience, further guided by our scientific advisory board which includes the world's leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
關於 Erasca
在埃拉斯卡，我們的名字就是我們的使命：消滅癌症。我們是一家臨床階段的精準腫瘤學公司，專注於爲RAS/MAPK路徑驅動的癌症患者發現、開發和商業化療法。我們公司由精準腫瘤學和RAS領域的領先先驅共同創立，旨在開發旨在全面關閉癌症患者治療的RAS/MAPK途徑的新療法和聯合方案。我們已經組裝了業內最深的以RAS/MAPK路徑爲重點的管道之一。我們相信，在包括RAS/MAPK途徑領域的世界領先專家在內的科學顧問委員會的進一步指導下，我們團隊的能力和經驗，使我們能夠獨特地實現消滅癌症的大膽使命。
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
聯繫人：
喬伊斯·阿萊爾
LifeSci 顧問有限公司
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
資料來源：Erasca, Inc.
Source: Erasca, Inc.
資料來源：Erasca, Inc.
譯文內容由第三人軟體翻譯。